Managing cognitive symptoms and fatigue in cholestatic liver disease
Introduction: Patients with cholestatic diseases may develop fatigue and cognitive symptoms. The impact of symptom burden may be significant in some patients. To date, there are no effective pharmacological therapies to improve cognitive symptoms or fatigue in cholestasis and we are wholly reliant on supportive approaches. Area covered: This review provides an overview of cognitive symptoms and fatigue in the cholestatic liver disease primary biliary cholangitis (PBC), including pathophysiology and our approach to the management of these symptoms. Expert opinion: The impact of fatigue and cognitive symptoms on the perceived quality of life can be profound for patients with PBC. The pathophysiology of these symptoms is complex and poorly understood, making the development of therapeutic trials of symptom-directed therapies challenging. The current recommended management for fatigue and cognitive symptoms is mainly supportive.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Expert review of gastroenterology & hepatology - 15(2021), 3 vom: 10. März, Seite 235-241 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Phaw, Naw April [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Central and peripheral fatigue |
|---|
| Anmerkungen: |
Date Completed 29.10.2021 Date Revised 10.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17474124.2021.1844565 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316997870 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316997870 | ||
| 003 | DE-627 | ||
| 005 | 20231225162312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17474124.2021.1844565 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM316997870 | ||
| 035 | |a (NLM)33131347 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Phaw, Naw April |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Managing cognitive symptoms and fatigue in cholestatic liver disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.10.2021 | ||
| 500 | |a Date Revised 10.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction: Patients with cholestatic diseases may develop fatigue and cognitive symptoms. The impact of symptom burden may be significant in some patients. To date, there are no effective pharmacological therapies to improve cognitive symptoms or fatigue in cholestasis and we are wholly reliant on supportive approaches. Area covered: This review provides an overview of cognitive symptoms and fatigue in the cholestatic liver disease primary biliary cholangitis (PBC), including pathophysiology and our approach to the management of these symptoms. Expert opinion: The impact of fatigue and cognitive symptoms on the perceived quality of life can be profound for patients with PBC. The pathophysiology of these symptoms is complex and poorly understood, making the development of therapeutic trials of symptom-directed therapies challenging. The current recommended management for fatigue and cognitive symptoms is mainly supportive | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cognitive symptoms | |
| 650 | 4 | |a central and peripheral fatigue | |
| 650 | 4 | |a cholestasis | |
| 650 | 4 | |a fatigue | |
| 650 | 4 | |a primary biliary cholangitis | |
| 700 | 1 | |a Leighton, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Dyson, Jessica Katharine |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, David Ej |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of gastroenterology & hepatology |d 2007 |g 15(2021), 3 vom: 10. März, Seite 235-241 |w (DE-627)NLM185080200 |x 1747-4132 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:3 |g day:10 |g month:03 |g pages:235-241 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17474124.2021.1844565 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 3 |b 10 |c 03 |h 235-241 | ||